These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1706639)

  • 1. Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma.
    Chappard D; Rossi JF; Bataille R; Alexandre C
    Calcif Tissue Int; 1991 Jan; 48(1):13-7. PubMed ID: 1706639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclast cytomorphometry in patients with femoral neck fracture.
    Chappard D; Baslé MF; Audran M; Benhamou CL; Rebel A
    Pathol Res Pract; 1996 Jun; 192(6):573-8. PubMed ID: 8857645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma.
    Rossi JF; Chappard D; Marcelli C; Laplante J; Commes T; Baldet P; Janbon C; Jourdan J; Alexandre C; Bataille R
    Br J Haematol; 1990 Dec; 76(4):469-75. PubMed ID: 2265108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast cytomorphometry and scanning electron microscopy of bone eroded surfaces during leukemic disorders.
    Chappard D; Rossi JF; Bataillle R; Alexandre C
    Scanning Microsc; 1990 Jun; 4(2):323-8. PubMed ID: 2402608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?
    Andersen TL; Boissy P; Sondergaard TE; Kupisiewicz K; Plesner T; Rasmussen T; Haaber J; Kølvraa S; Delaissé JM
    J Pathol; 2007 Jan; 211(1):10-7. PubMed ID: 17083146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
    Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
    Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption.
    Moonga BS; Moss DW; Patchell A; Zaidi M
    J Physiol; 1990 Oct; 429():29-45. PubMed ID: 2277349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases.
    Rossi JF; Bataille R; Chappard D; Alexandre C; Janbon C
    Am J Med; 1987 Jul; 83(1):10-6. PubMed ID: 3496790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Walker 256/B malignant breast cancer cells disrupt osteoclast cytomorphometry and activity in rats: modulation by α-tocopherol acetate.
    Badraoui R; Ben-Nasr H; Amamou S; El-May MV; Rebai T
    Pathol Res Pract; 2014 Mar; 210(3):135-41. PubMed ID: 24314812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomorphometry of osteoclasts.
    Chappard D; Azema J; Alexandre C; Becker JM
    Med Lab Sci; 1989 Oct; 46(4):363-6. PubMed ID: 2615587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
    Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
    Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional osteoclast-like transformation of cultured human myeloma cell lines.
    Calvani N; Cafforio P; Silvestris F; Dammacco F
    Br J Haematol; 2005 Sep; 130(6):926-38. PubMed ID: 16156862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.
    Raimondi L; De Luca A; Amodio N; Manno M; Raccosta S; Taverna S; Bellavia D; Naselli F; Fontana S; Schillaci O; Giardino R; Fini M; Tassone P; Santoro A; De Leo G; Giavaresi G; Alessandro R
    Oncotarget; 2015 May; 6(15):13772-89. PubMed ID: 25944696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical characterization of osteoclasts and osteoclast-like cells with monoclonal antibody MB1 on paraffin-embedded tissues.
    Chilosi M; Gilioli E; Lestani M; Menestrina F; Fiore-Donati L
    J Pathol; 1988 Nov; 156(3):251-4. PubMed ID: 2904980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research on mechanism underlying bone damage in myeloma--review].
    Zhou LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1340-4. PubMed ID: 18088497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
    Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
    Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.